ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
BriaCell Therapeutics Corporation

BriaCell Therapeutics Corporation (BCTX)

0.6612
-0.4388
(-39.89%)
終了 12月13日 6:00AM
0.655
-0.0062
(-0.94%)
取引時間後: 9:45AM

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
0.655
買値
0.655
売値
0.6799
出来高
7,931,823
0.595 日の範囲 0.71
0.4641 52 週間の範囲 5.97
時価総額
前日終値
1.10
始値
0.69
最終取引時間
財務取引量
US$ 5,214,307
VWAP
0.657391
平均取引量 (3 か月)
2,549,540
発行済株式数
35,838,161
配当利回り
-
PER
-79.28
1 株当たり利益 (EPS)
-0.13
歳入
-
純利益
-4.79M

BriaCell Therapeutics Corporation について

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. 詳細を表示

セクター
Aircraft
業界
Business Services, Nec
ウェブサイト
本社
Vancouver, British Columbia, Can
設立
2009
BriaCell Therapeutics Corporation is listed in the Aircraft sector of the ナスダック市場 with ticker BCTX. The last closing price for BriaCell Therapeutics was US$1.10. Over the last year, BriaCell Therapeutics shares have traded in a share price range of US$ 0.4641 to US$ 5.97.

BriaCell Therapeutics currently has 35,838,161 shares in issue. The market capitalisation of BriaCell Therapeutics is US$39.42 million. BriaCell Therapeutics has a price to earnings ratio (PE ratio) of -79.28.

BCTX 最新ニュース

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BriaCell Therapeutics Announces Proposed Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the...

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus an immune check point inhibitor in metastatic...

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer...

BriaCell Provides Update to its Board of Directors

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic breast cancerBria-OTS™ to be studied as monotherapy and in combination...

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical modelsNovel therapy activates...

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations...

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patientsMultiple...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.395-37.6190476191.051.260.6532280041.10483647CS
40.01622.536005009390.63881.260.55518551550.98280791CS
120.11521.29629629630.541.420.532725495400.88753697CS
26-0.665-50.37878787881.321.960.464128946530.74344223CS
52-3.855-85.47671840354.515.970.464115144110.82360843CS
156-7.0606-91.51070558357.715612.090.46417415182.88781493CS
260-3.585-84.55188679254.2412.470.464111359204.59906183CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
SHOTWSafety Shot Inc
US$ 0.25
(79.21%)
29.07k
PALIPalisade Bio Inc
US$ 2.36
(68.57%)
68.2M
LAESSEALSQ Corporation
US$ 1.8401
(60.01%)
256.77M
HIMXHimax Technologies Inc
US$ 9.73
(45.22%)
20.06M
TRVITrevi Therapeutics Inc
US$ 3.60
(44.58%)
63.85M
SPGCSacks Parente Golf Inc
US$ 0.3621
(-74.14%)
29.71M
KROSKeros Therapeutics Inc
US$ 18.40
(-73.20%)
14.65M
TFFPTFF Pharmaceuticals Inc
US$ 0.0657
(-59.62%)
13.29M
SFHGSamfine Creation Holdings Group Ltd
US$ 1.27
(-58.36%)
7.38M
APVOAptevo Therapeutics Inc
US$ 5.60
(-44.06%)
6.49M
GOEVCanoo Inc
US$ 0.1737
(33.62%)
970.79M
LAESSEALSQ Corporation
US$ 1.8401
(60.01%)
256.77M
NVDANVIDIA Corporation
US$ 137.34
(-1.41%)
159.23M
RGTIRigetti Computing Inc
US$ 5.9591
(-19.25%)
158.72M
CDTConduit Pharmaceuticals Inc
US$ 0.0798
(-9.63%)
119.28M

BCTX Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock